Literature DB >> 12008025

Alteration of nuclear glyceraldehyde-3-phosphate dehydrogenase structure in Huntington's disease fibroblasts.

Jennifer L Mazzola1, Michael A Sirover.   

Abstract

The expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) may be involved in neuronal disease and in programmed cell death. Recent investigations indicate an in vitro physical association between GAPDH and huntingtin, the mutated protein in Huntington's disease (HD). Previous studies reveal the functional diversity of GAPDH as a membrane, cytoplasmic and nuclear protein. These activities are independent of its classical glycolytic function. Thus, huntingtin-GAPDH interactions could affect not only energy production but also result in pleiotropic effects involving various biochemical pathways in HD cells. We now report the identification of a nuclear high molecular weight (HMW) GAPDH species in Huntington's disease cells. In contrast, nuclei from age-matched control normal human cells did not contain the HMW GAPDH species. Further, this GAPDH structure was not observed in HD whole cell sonicates which are characterized by normal GAPDH activity. The disruption of intracellular structure is implicit in the preparation of whole cell sonicates. Therefore, these results suggest that the dissociation of the GAPDH protein from its high molecular weight structure results in the recovery of its function. These findings reveal a singular, new subcellular phenotype in HD cells. As such, they indicate an interrelationship between nuclear GAPDH function and huntingtin localization in this CAG expansion neuronal disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12008025     DOI: 10.1016/s0169-328x(02)00160-2

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  9 in total

Review 1.  The diverse functions of GAPDH: views from different subcellular compartments.

Authors:  Carlos Tristan; Neelam Shahani; Thomas W Sedlak; Akira Sawa
Journal:  Cell Signal       Date:  2010-08-19       Impact factor: 4.315

Review 2.  Protein S-nitrosylation: role for nitric oxide signaling in neuronal death.

Authors:  Neelam Shahani; Akira Sawa
Journal:  Biochim Biophys Acta       Date:  2011-07-23

3.  A dimer interface mutation in glyceraldehyde-3-phosphate dehydrogenase regulates its binding to AU-rich RNA.

Authors:  Michael R White; Mohd M Khan; Daniel Deredge; Christina R Ross; Royston Quintyn; Beth E Zucconi; Vicki H Wysocki; Patrick L Wintrode; Gerald M Wilson; Elsa D Garcin
Journal:  J Biol Chem       Date:  2014-12-01       Impact factor: 5.157

4.  Creatine supplementation lowers brain glutamate levels in Huntington's disease.

Authors:  Andreas Bender; Dorothee P Auer; Thomas Merl; Ralf Reilmann; Phillip Saemann; Alexander Yassouridis; Julia Bender; Adolf Weindl; Matthias Dose; Thomas Gasser; Thomas Klopstock
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

Review 5.  Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders.

Authors:  Mark D Berry
Journal:  J Psychiatry Neurosci       Date:  2004-09       Impact factor: 6.186

6.  Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH.

Authors:  Byoung-Il Bae; Makoto R Hara; Matthew B Cascio; Cheryl L Wellington; Michael R Hayden; Christopher A Ross; Hyo Chol Ha; Xiao-Jiang Li; Solomon H Snyder; Akira Sawa
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

Review 7.  The energetics of Huntington's disease.

Authors:  Susan E Browne; M Flint Beal
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

8.  Testis-specific glyceraldehyde-3-phosphate dehydrogenase: origin and evolution.

Authors:  Mikhail L Kuravsky; Vladimir V Aleshin; Dmitrij Frishman; Vladimir I Muronetz
Journal:  BMC Evol Biol       Date:  2011-06-10       Impact factor: 3.260

9.  Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model.

Authors:  Marie Thérèse Besson; Karin Alegría; Pamela Garrido-Gerter; Luis Felipe Barros; Jean-Charles Liévens
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.